Immuno-Oncology Learning Library

Oncology Nursing Society articles:

Clinical Update: Focus on Clinical Experiences With CAR T-Cell Therapy
_{This resource was produced by ONS and supported by funding from Janssen Oncology/Legend Biotech.}

Clinical Update: A Focus Group on Immuno-oncology, Navigation, Precision Oncology, and Immune-related Adverse Events

Clinical Journal of Oncology Nursing Articles:

Management of Immunotherapy Infusion Reactions

CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Immunotherapy Assessment: Using a Survey Instrument to Examine Oncology Nurses' Confidence Levels with Administration and Management

SmartPhrase: Development of an Electronic Health Record System to Promote Chemotherapy and Immunotherapy Safety

CAR T-Cell Therapy: Updates in Nursing Management

Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients with Stage III Non-Small Cell Lung Cancer

Orthostatic Vital Signs Algorithm: Decreasing Falls in Patients Undergoing Blood and Marrow Transplants or Treatment With Cellular Immunotherapy

Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management

STAT: Cytokine Release Syndrome

STAT: Tumor Lysis Syndrome

Immunotherapy Summit: Proceedings and Identified Priorities for Safe Administration and Care

Immunotherapy Administration: Oncology Nursing Society Recommendations

ONS Voice articles:

Drug Reference Sheets

Postdischarge ICI Patient Education Eliminates Hospital Readmissions

Text-Messaging Prescreening Streamlines Treatment Visits and Care for ICI Toxicities

What the Evidence Says About Probiotics and Cancer Immunotherapy

Tumor-Infiltrating Lymphocytes Active Immune Response to Metastatic Breast Cancer

Oncology Drug Reference Sheet: Nivolumab and Relatlimab-Rmbw

Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy

Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes

CAR T-Cell Therapy Programs: Essential Elements to Establish a Successful System

First-Line Combination Immunotherapy Prolongs Survival in BRAF Advanced Melanoma

Fiber- but not Probiotics- Boosts Immunotherapy Response for Melanoma

Nursing Considerations for ICI-Related Myocarditis

Immunotherapy After Surgery May Prevent Early-Stage Melanoma Recurrence

Evidence Defines Nursing Implications for Combination Cancer Treatment Side Effects

Today's Immunotherapy Combinations: Radiation is the Next Wave to Unleash the Power of Boosting the Immune System

Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology

Here’s Why Oncology Nurses Are Pivotal in Managing Immune-Related Adverse Events

Guide to Cancer Immunotherapy 

Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition)

Chimeric Antigen Receptor T-Cell Therapy: A Timeline of Events and Adverse Events
_{This resource was developed by ONS through a sponsorship from Janssen Oncology.}

Cytokine Release Syndrome

Safe Handling of Checkpoint Inhibitors

Safe Handling of Oncolytic Viruses

Immunotherapy Wallet Card

Immunotherapy Wallet Card - Spanish

Nursing Considerations for CAR T-cell Therapy for Patients with Hematologic Malignancies: Patient Education and Symptom Management 
_{This resource was developed by ONS through a sponsorship from Janssen Oncology.}

Fundamentals of Chemotherapy Immunotherapy Administration

ONS/ONCC Chemotherapy Immunotherapy Certificate Course

Fundamentals of Chemotherapy Immunotherapy Administration Renewal

ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal Course

Immuno-Oncology Game Show
Download the facilitator guide if you'd like to use the game in a group setting such as a staff meeting or chapter meeting.

Huddle Cards

Monoclonal Antibodies

Oncogenic Viruses

Tumor Lysis Syndrome

Cytokine Release Syndrome

Immunotherapy

Episode 267: Side-Effect Management for CAR T-Cell Therapy for Hematologic Malignancies
_{This podcast episode is produced by ONS and supported by funding from Janssen Oncology/Legend Biotech.}

Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation
_{This podcast episode is produced by ONS and supported by funding from Janssen Oncology/Legend Biotech.}

Episode 242: Oncology Pharmacology 2023: Today's Treatments and Tomorrow's Breakthroughs

Episode 184: Oncologic Emergencies 101: Tumor Lysis Syndrome

Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome

Episode 152: Administer Rituximab Immunotherapy With Confidence

Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment

Episode 98: Combination Immunotherapy Treatments

Episode 80 - Patients Need Checkpoint Inhibitor Education

Episode 63 - Immunotherapy Communication Challenges 

Episode 54 - Immunotherapy Collaboration Opportunities

Episode 40 - Breaking Down Checkpoint Inhibitors 

Episode 5 - New Guidelines for Managing Immunotherapy-Related Adverse Events 

Episode 1 - Experiences with CAR T-cell Therapy 

Education of the Nurse Who Administers and Cares for the Individual Receiving Chemotherapy, Targeted Therapy, and Immunotherapy

Immunotherapy-Induced Diarrhea

Skin Toxicities

Cancer Treatment Therapies Overview
^{Funding for development of this activity was provided by an independent educational grant from Bristol-Myers Squibb.}

Pseudoprogression 

Speed Talk: Checkpoint Inhibitors in 5 Minutes

Checkpoint Inhibitors: Entering a New Era in Cancer Treatment

CAR T-Cell Therapy

Balancing irAEs

CAR T-cell Therapy: Foundational Knowledge and Best Practices
_{This resource was developed by ONS through a sponsorship from Janssen Oncology.} 

2020 Webinar: Immuno-Oncology for the Oncology Nurse (download slides here)
_{Funding for development of this activity was provided by an independent educational grant from Bristol-Myers Squibb.}